Overview

* Roivant Q2 revenue declines, missing analyst expectations for income from operations

* Company maintains strong cash position of $4.4 bln, supporting cash runway into profitability

* Brepocitinib Phase 3 study in dermatomyositis shows significant improvement over placebo

Outlook

* Roivant plans NDA filing for brepocitinib in DM in H1 2026

* Immunovant expects TED study results in H1 2026

Result Drivers

* Research and development (R&D) expenses increased by $21.5 million to $164.6 million for the three months ended September 30, 2025, compared to $143.1 million for the three months ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $1.57

Revenue mln

Q2 EPS -$0.17

Q2 Net -$166.04

Income mln

Q2 Miss -$306.23 -$278.40

Income mln mln (7

From Analysts

Operatio )

ns

Q2 $307.80

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for Roivant Sciences Ltd ( ROIV ) is $20.50, about 0.6% below its November 7 closing price of $20.62

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)